NIH Study Maps Molecular Drivers of Alzheimer's and Brain Disorders
NIH-supported PsychAD research mapped molecular drivers of Alzheimer’s and related brain disorders using a single-cell atlas of over 6.3 million nuclei from 1,494 donors.<br />
Neuropsychiatric Disorders | 28/09/2026 | By News Bureau
Andera Partners participated in Exciva’s Euro 51 million Series B round to advance Deraphan into Phase II trials for agitation in Alzheimer’s disease across Europe and North America.
Neuropsychiatric Disorders | 23/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy